SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel To Find Variants in Real Time.

Autor:	Ashford F; Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Best A; Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Dunn SJ; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Ahmed Z; Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Siddiqui H; Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Melville J; Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Wilkinson S; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Mirza J; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Cumley N; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Stockton J; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Ferguson J; Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Wheatley L; Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Ratcliffe E; Department of Clinical Microbiology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom., Casey A; Department of Clinical Microbiology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom., Plant T; Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Quick J; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Richter A; Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Loman N; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., McNally A; Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birminghamgrid.6572.6, Birmingham, United Kingdom.
Jazyk:	angličtina
Zdroj:	Journal of clinical microbiology [J Clin Microbiol] 2022 Apr 20; Vol. 60 (4), pp. e0240821. Date of Electronic Publication: 2022 Apr 04.
DOI:	10.1128/jcm.02408-21
Abstrakt:	Genome sequencing is a powerful tool for identifying SARS-CoV-2 variant lineages; however, there can be limitations due to sequence dropout when used to identify specific key mutations. Recently, ThermoFisher Scientific has developed genotyping assays to help bridge the gap between testing capacity and sequencing capability to generate real-time genotyping results based on specific variants. Over a 6-week period during the months of April and May 2021, we set out to assess the ThermoFisher TaqMan mutation panel genotyping assay, initially for three mutations of concern and then for an additional two mutations of concern, against SARS-CoV-2-positive clinical samples and the corresponding COVID-19 Genomics UK Consortium (COG-UK) sequencing data. We demonstrate that genotyping is a powerful in-depth technique for identifying specific mutations, is an excellent complement to genome sequencing, and has real clinical health value potential, allowing laboratories to report and take action on variants of concern much more quickly.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu